Zyversa Therapeutics Stock Book Value Per Share
| ZVSA Stock | 1.13 0.01 0.88% |
ZyVersa Therapeutics fundamentals help investors to digest information that contributes to ZyVersa Therapeutics' financial success or failures. It also enables traders to predict the movement of ZyVersa Stock. The fundamental analysis module provides a way to measure ZyVersa Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ZyVersa Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 113.58 | 107.90 | |
| Tangible Book Value Per Share | (77.67) | (81.56) |
ZyVersa | Book Value Per Share |
ZyVersa Therapeutics Company Book Value Per Share Analysis
ZyVersa Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current ZyVersa Therapeutics Book Value Per Share | 27.33 X |
Most of ZyVersa Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ZyVersa Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ZyVersa Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for ZyVersa Therapeutics is extremely important. It helps to project a fair market value of ZyVersa Stock properly, considering its historical fundamentals such as Book Value Per Share. Since ZyVersa Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ZyVersa Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ZyVersa Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
ZyVersa Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of ZyVersa Therapeutics is about 27.331 times. This is 1707.71% lower than that of the Biotechnology sector and 110.99% lower than that of the Health Care industry. The book value per share for all United States stocks is 98.59% higher than that of the company.
ZyVersa Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ZyVersa Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ZyVersa Therapeutics could also be used in its relative valuation, which is a method of valuing ZyVersa Therapeutics by comparing valuation metrics of similar companies.ZyVersa Therapeutics is currently under evaluation in book value per share category among its peers.
ZyVersa Fundamentals
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (480.08 K) | ||||
| Shares Outstanding | 2.34 M | ||||
| Shares Owned By Insiders | 0.61 % | ||||
| Shares Owned By Institutions | 4.47 % | ||||
| Number Of Shares Shorted | 45.48 K | ||||
| Price To Book | 0.38 X | ||||
| EBITDA | (107.74 M) | ||||
| Net Income | (98.3 M) | ||||
| Total Debt | 8.66 K | ||||
| Book Value Per Share | 27.33 X | ||||
| Cash Flow From Operations | (8.72 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | 491.97 X | ||||
| Target Price | 20.0 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 2.65 M | ||||
| Total Asset | 22.11 M | ||||
| Retained Earnings | (103.22 M) | ||||
| Working Capital | (6.84 M) | ||||
| Net Asset | 22.11 M |
About ZyVersa Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ZyVersa Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ZyVersa Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ZyVersa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out ZyVersa Therapeutics Piotroski F Score and ZyVersa Therapeutics Altman Z Score analysis. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 491.97 | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.